Department of Surgery and Molecular Oncology, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.
J Pathol. 2010 Mar;220(4):401-3. doi: 10.1002/path.2674.
A p53 network immunohistochemically-based signature to discriminate between good and poor prognosis breast cancer would have clinical relevance, given the key role of p53 in malignancy and response to therapy. Utilizing a five-protein signature of p53/mdm2/mdm4/bcl2/p21 discriminates good-prognosis and poor-prognosis patient groups, based on the functionality of the p53 network. However, the relationship of this five-protein signature to p53 mutation, the wide range of breast cancer therapies now in use and the over-70 age group remain uncertain. Nonetheless, confirmation of the signature in two independent series suggests that this approach should be considered in further case series and in the context of clinical trials.
鉴于 p53 在恶性肿瘤和对治疗的反应中的关键作用，如果有一种基于 p53 网络免疫组织化学的签名能够区分预后良好和预后不良的乳腺癌，那么它将具有临床意义。利用 p53/mdm2/mdm4/bcl2/p21 的五蛋白签名，可以根据 p53 网络的功能区分预后良好和预后不良的患者群体。然而，这种五蛋白签名与 p53 突变、目前广泛使用的乳腺癌治疗方法以及 70 岁以上的年龄组之间的关系尚不确定。尽管如此，在两个独立的系列中对该签名的确认表明，这种方法应该在进一步的病例系列中以及临床试验中进行考虑。
